Patients Hospitalized for COVID-19 in the Periods of Delta and Omicron Variant Dominance in Greece: Determinants of Severity and Mortality.
COVID-19
Delta
Omicron
SARS-CoV-2
mortality
variant
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 Sep 2023
11 Sep 2023
Historique:
received:
15
08
2023
revised:
03
09
2023
accepted:
07
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) has been a pandemic since 2020, and depending on the SARS-CoV-2 mutation, different pandemic waves have been observed. The aim of this study was to compare the baseline characteristics of patients in two phases of the pandemic and evaluate possible predictors of mortality. This is a retrospective multicenter observational study that included patients with COVID-19 in 4 different centers in Greece. Patients were divided into two groups depending on the period during which they were infected during the Delta and Omicron variant predominance. A total of 979 patients (433 Delta, 546 Omicron) were included in the study (median age 67 years (54, 81); 452 [46.2%] female). Compared to the Omicron period, the patients during the Delta period were younger (median age [IQR] 65 [51, 77] vs. 70 [55, 83] years, In the Omicron wave, patients were older with a higher number of comorbidities, but patients with the Delta variant had more severe disease and a longer duration of hospitalization.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) has been a pandemic since 2020, and depending on the SARS-CoV-2 mutation, different pandemic waves have been observed. The aim of this study was to compare the baseline characteristics of patients in two phases of the pandemic and evaluate possible predictors of mortality.
METHODS
METHODS
This is a retrospective multicenter observational study that included patients with COVID-19 in 4 different centers in Greece. Patients were divided into two groups depending on the period during which they were infected during the Delta and Omicron variant predominance.
RESULTS
RESULTS
A total of 979 patients (433 Delta, 546 Omicron) were included in the study (median age 67 years (54, 81); 452 [46.2%] female). Compared to the Omicron period, the patients during the Delta period were younger (median age [IQR] 65 [51, 77] vs. 70 [55, 83] years,
CONCLUSIONS
CONCLUSIONS
In the Omicron wave, patients were older with a higher number of comorbidities, but patients with the Delta variant had more severe disease and a longer duration of hospitalization.
Identifiants
pubmed: 37762846
pii: jcm12185904
doi: 10.3390/jcm12185904
pmc: PMC10531654
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Gastroenterol. 2017 Sep;112(9):1389-1396
pubmed: 28440304
Clin Pract. 2021 Oct 21;11(4):778-784
pubmed: 34698149
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
J Coll Physicians Surg Pak. 2023 Mar;33(3):297-302
pubmed: 36945160
J Pharm Anal. 2020 Apr;10(2):123-129
pubmed: 32292624
Crit Care. 2020 Nov 16;24(1):647
pubmed: 33198786
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Heart. 2020 Aug;106(15):1132-1141
pubmed: 32354800
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Lancet Glob Health. 2022 Jul;10(7):e961-e969
pubmed: 35597249
Front Immunol. 2021 Oct 22;12:741061
pubmed: 34745112
BMC Infect Dis. 2021 Jul 8;21(1):663
pubmed: 34238232
Am J Emerg Med. 2021 Jan;39:173-179
pubmed: 33069541
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Blood. 2019 Feb 28;133(9):906-918
pubmed: 30642917
Trends Cardiovasc Med. 2021 Apr;31(3):143-160
pubmed: 33338635
J Mol Cell Biol. 2021 Jul 6;13(3):161-167
pubmed: 33226078
J Pers Med. 2023 May 29;13(6):
pubmed: 37373897
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Turk Thorac J. 2022 Mar;23(2):145-153
pubmed: 35404247
J Med Virol. 2022 Apr;94(4):1255-1256
pubmed: 34850421
J Intern Med. 2022 Aug;292(2):385-387
pubmed: 35417053
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223
pubmed: 35143466
Ann Palliat Med. 2021 Mar;10(3):2723-2735
pubmed: 33549005
JAMA. 2022 Apr 5;327(13):1286-1288
pubmed: 35175280
Radiol Cardiothorac Imaging. 2020 Oct 01;2(5):e200389
pubmed: 33778629
Clin Infect Dis. 2023 Feb 8;76(3):e18-e25
pubmed: 36041009
Inflammation. 2023 Feb;46(1):297-312
pubmed: 36215001
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
BMJ. 2020 Mar 12;368:m1036
pubmed: 32165426
J Hum Hypertens. 2021 Jan;35(1):4-11
pubmed: 32719447
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211010976
pubmed: 33926262
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
J Immunol. 2021 May 1;206(9):2146-2159
pubmed: 33846224
Biosens Bioelectron. 2021 Jan 15;172:112752
pubmed: 33126180
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Int J Mol Sci. 2023 May 10;24(10):
pubmed: 37239895
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Can J Respir Ther. 2022 Jul 26;58:98-102
pubmed: 35928232
BMJ. 2022 Aug 2;378:e070695
pubmed: 35918098
Am J Hematol. 2020 Dec;95(12):1578-1589
pubmed: 32857878